Compare Eli Lilly And Co (LLY) vs PubMatic Inc (PUBM) Price & Performance

Eli Lilly (LLY) trades at $1,176.69, down 1.01% on the day, amid a bullish technical outlook and strong fundamental performance. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $8.38 surpassing the $6.40 consensus. Revenue surged to $65.18B in 2025, driving a net income margin of 33.53%. Recent news highlights promising pipeline developments in weight-loss and diabetes drugs, reinforcing growth prospects.

The outlook remains positive given robust revenue growth, high profitability, and analyst consensus favoring buys. Key risks include elevated valuation multiples and competitive pressures in the pharmaceutical sector. With a consensus price target of $1,350, upside potential exists, but investors should weigh execution risks against the company's innovation pipeline.

PubMatic (PUBM) trades at $18.72, up 0.81% with bullish technical signals from moving averages. The company shows mixed fundamentals with strong revenue growth but negative profitability metrics, including a -4.66% net margin. Recent Q2 2026 earnings beat expectations with -$0.03 EPS versus -$0.18 expected, while analyst consensus remains strongly positive with 11 buy ratings and a $19.89 price target. Operating cash flow improved to $81M in 2025, supporting business stability.

The outlook suggests potential upside near analyst targets, though profitability challenges and CFO transition pose risks. Revenue growth in mobile app and CTV segments provides catalysts, while high P/E of 132 indicates premium valuation. Investment opportunity exists for growth-focused investors tolerant of current losses, with sentiment supported by AI-driven ad tech adoption.